ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2130

Factors Associated With Two-Year Pain Experience Outcome In Knee Osteoarthritis

Jamie E. Rayahin1, Joan S. Chmiel2, Orit Almagor2, Laura Belisle2, Alison H. Chang3, Kirsten Moisio2, Karen W. Hayes2, Yunhui Zhang2 and Leena Sharma2, 1University of Illinois, Chicago, Chicago, IL, 2Northwestern University, Chicago, IL, 3Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Knee, Osteoarthritis, pain and psychosocial factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis.

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Few strategies to improve pain outcome in knee OA exist, in part because methods to evaluate this outcome are not established.  ICOAP development included formulation of pain experience stages (Hawker 2008): 1) predictable pain, known trigger, only limiting high impact activity; 2) mixed predictable/unpredictable pain, more constant, affecting some daily activities; 3) pain constant, superimposed unpredictable, major activity avoidance.  We hypothesized that the probability of a good pain experience outcome is associated inversely with baseline depression and pain catastrophizing and directly with self-efficacy and social support.

Methods:   Study participants (all with knee OA) reported pain stage (no pain, or stages 1, 2, or 3) at baseline and 2 years.  1-month test-retest reliability was excellent (weighted κ = 0.85; n = 28).  Baseline assessments utilized the Geriatric Depression Scale, Pain Catastrophizing Scale, function Arthritis Self-Efficacy Scale, and MOS Social Support Survey.  Good outcome was defined: baseline → 2-year reports of (no pain or stage 1) → (no pain or stage 1) or (stage 2 or 3) → (no pain or stage 1).  Poor outcome was: (stage 2 or 3) → (stage 2 or 3) or (no pain or stage 1) → (stage 2 or 3).  In multivariable logistic regression, pain outcome was the dependent variable, and all baseline variables with univariate p ≤ 0.20 potential predictors.

Results:  212 persons [163 (77%) women, mean age 65 (10, SD), BMI 28.5 (5.7)] comprised the sample. 136 (64%) had a good pain outcome and 76 (36%) a poor outcome.  Several baseline factors were associated with good pain outcome in univariate analyses (Table 1).  In multivariable analysis, higher self-efficacy was associated with a significantly higher likelihood of good outcome; higher pain catastrophizing and BMI were associated with a lower likelihood of good outcome (Table 2).

Conclusion:   The odds of a good 2-year pain experience outcome in knee OA were lower in persons with greater pain catastrophizing and/or higher BMI, and higher in persons with greater self-efficacy.  Specifically targeting these factors may help improve pain outcome in knee OA.

Table 1.  Baseline Characteristics of Good and Poor 2-Year Pain Experience Outcome Groups

Baseline Characteristics

Good Pain Experience Outcome*

(n = 136 persons)

Poor Pain Experience Outcome*

(n = 76 persons)

p value

Pain catastrophizing (higher score worse)

4.3 (4.7)

10.6 (8.5)

<0.0001

Self-efficacy (higher better)

27.1 (3.5)

22.8 (6.4)

<0.0001

Social support (higher better)

58.0 (16.4)

55.9 (15.2)

0.66

Age, years

65.7 (10.1)

62.7 (10.0)

0.91

Women, number (%)

107 (78.7%)

56 (73.7%)

0.50

BMI, kg/m2

27.1 (4.6)

31.1 (6.6)

0.0004

Extensor strength, N-M (worse of R and L)

108.6(28.0)

97.6 (30.4)

0.40

K/L grade

(worse of R and L)

 

0-1

16 (11.8%)

7 (9.2%)

0.0045

2

77 (56.6%)

26 (34.2%)

3

18 (13.2%)

16 (21.1%)

4

25 (18.4%)

27 (35.5%)

Depression (presence)**              

2 (1.5%)

3 (3.9%)

0.35

Comorbidity***

0.8 (1.4)

1.5 (2.2)

<0.0001

Back pain, number (%)

93 (68.4%)

62 (81.6%)

0.052

Hip pain, number (%)

56 (41.2%)

33 (43.4%)

0.77

Physical activity (PASE)

152.8 (73.5)

157.8 (99.4)

0.0023

Medication use, number (%)

52 (38.2%)

43 (56.6%)

0.014

*Value shown is mean (SD) unless otherwise indicated

**p value for depressive symptoms as a continuous variable also exceeded 0.20

***Comorbidity questionnaire modification of Charlson Index (continuous)

 

 

Table 2.  Multivariable Logistic Regression Model: Associations between Baseline Covariables and Baseline-to-2-Year Good Pain Experience Outcome (Dependent Variable) 

Findings are adjusted for all other variables in the table.

 

Independent Variable

Adjusted Odds Ratio (95% CI)

Pain catastrophizing per 1 unit

0.87 (0.82-0.93)

Self-efficacy per 1 unit

1.12 (1.03-1.22)

BMI per 1 kg/m2

0.93 (0.86-0.995)

K/L grade 2 (vs. 0-1, reference)

2.08 (0.59-7.33)

K/L grade 3 (vs. 0-1, reference)

0.33 (0.08-1.32)

K/L grade 4 (vs. 0-1, reference)

0.52 (0.14-1.97)

Comorbidity per 1 unit

0.86 (0.67-1.09)

Back pain (vs. no back pain, reference)

0.55 (0.23-1.36)

Physical activity (PASE) per 1 unit

0.997 (0.993-1.001)

Medication use (vs. no use, reference)

0.67 (0.32-1.38)

 


Disclosure:

J. E. Rayahin,
None;

J. S. Chmiel,
None;

O. Almagor,
None;

L. Belisle,
None;

A. H. Chang,
None;

K. Moisio,
None;

K. W. Hayes,
None;

Y. Zhang,
None;

L. Sharma,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-two-year-pain-experience-outcome-in-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology